Survey Finds Arthritis Patients Are Using Cannabis For Joint Pain
Missouri cannabis team reviewing licensing and compliance documents
Medical cannabis demand continues to show up in patient reported data. International Cannabis Business Conference reports that a new survey found 15.8 percent of arthritis patients surveyed had used cannabis in the past year to control pain, while 26.3 percent had previously used cannabis for medical purposes. The study, published in the Journal of International Medical Research, surveyed 406 arthritis and joint pain patients at three orthopedic clinics in Canada. Patients reported that cannabis may help reduce arthritis pain and replace part of their use of other pain medications, adding to the broader conversation around medical cannabis access, physician guidance, and regulated product education.
Quick facts
• The survey included 406 arthritis and joint pain patients
• 26.3 percent had previously used cannabis for medical purposes
• 15.8 percent had used cannabis in the past year to control pain
• 63.1 percent of patients were prescribed analgesics for current musculoskeletal pain
• 64.5 percent of those prescribed analgesics were prescribed opioids
• 30.5 percent of patients prescribed opioids had used them in the last week
• Patients estimated cannabis could treat 53.6 percent of their pain on average
• Patients estimated cannabis could replace 50.4 percent of their analgesic medications on average
• 88.8 percent of patients who answered the question believed cannabis would aid pain management
• The universal operator lesson is simple: patient demand is real, but clinical education, safe access, and product guidance still matter
If medical cannabis patient demand is affecting your growth plan, complete our quick Cannashield intake form so you can map product, education, compliance, and insurance exposure before patient interest outpaces your operating structure.
Why this survey matters
This survey matters because arthritis is one of the most common chronic pain conditions in the world. Patients often deal with long term pain, stiffness, limited mobility, and ongoing medication decisions. That makes arthritis an important category for medical cannabis companies, clinicians, product educators, and investors watching where patient demand is coming from.
The study does not prove cannabis is a cure for arthritis. It is a survey of patient perceptions. That distinction matters. But patient perception still has business and healthcare value because it shows what patients are trying, what they believe helps, and where they may be seeking alternatives or supplements to existing pain management.
For operators, that means arthritis related demand should not be treated like hype. It should be treated like a patient access and education issue.
Why pain medication replacement is the key signal
One of the strongest signals in the study is medication replacement. Patients estimated that cannabis could replace about half of their analgesic medication use on average. The researchers also found that many patients were already using prescription and nonprescription pain options, including opioids and anti inflammatory drugs.
That does not mean patients should stop prescribed medications without a clinician. It does mean that patients are thinking about cannabis in relation to their broader pain management routine. That creates pressure on medical cannabis programs to offer clear product information, dosing guidance, risk education, and better clinician communication.
This is the universal operator lesson. Patient demand becomes safer and more durable when it is supported by proper medical guidance.
If uncertainty around patient education, product positioning, or medical claims is affecting how you plan, complete our Cannashield questionnaire to pressure test your exposure before demand turns into compliance risk.
Why clinicians are part of the market
The study found that patients felt comfortable discussing cannabis use with physicians. That is important because medical cannabis markets work best when clinicians are part of the conversation. If patients are already using cannabis but do not discuss it with healthcare providers, risks can increase around drug interactions, overuse, inconsistent dosing, and unrealistic expectations.
Healthcare providers also need better evidence. Patient reported outcomes are useful, but they should sit alongside clinical trials, real world evidence, safety monitoring, and product quality data. The more data clinicians have, the easier it becomes to guide patients responsibly.
For operators, that means the next stage of medical cannabis growth cannot rely only on consumer interest. It needs physician education, compliant marketing, accurate labels, clear product categories, and trusted supply.
Medical cannabis product guidance for arthritis pain patients
Why product strategy matters
Arthritis patients may not all want the same product. Some may prefer oils, capsules, topicals, balanced cannabinoid products, low dose options, or products with more predictable onset. Others may be looking for sleep support, inflammation related relief, or reduced pain medication burden.
That product diversity matters. A market that only focuses on high THC flower may miss many arthritis patients who are older, cautious, medication sensitive, or seeking more clinical guidance. Medical cannabis companies that serve this audience need consistency, testing, documentation, and patient friendly education.
If you need to organize product, patient education, clinical, and insurance records before expanding medical access, use the Cannashield intake form to identify weak points and build a cleaner patient focused strategy.
You might also like
Conclusion
The arthritis patient survey adds another useful data point to the medical cannabis conversation. A meaningful share of patients have already used cannabis for joint pain, and many believe it may help reduce pain and replace part of their use of other pain medications.
For operators, medical cannabis companies, healthcare providers, investors, and compliance teams, the message is simple. Patient demand is already here. The real challenge is building regulated access, better education, reliable products, responsible claims, and stronger clinical guidance around that demand.
Educational note: This article is for education only and is not legal, regulatory, medical, clinical, financial, product safety, or insurance advice. Patients should speak with a qualified healthcare provider before changing treatment or medication use.
What To Do This Week
• Review whether your medical cannabis education materials address arthritis and joint pain responsibly
• Check that product claims avoid overstating clinical outcomes or promising pain relief
• Identify product formats that may fit older patients or patients seeking predictable dosing
• Review clinician education resources and patient consultation workflows
• Confirm labels, testing records, and product documentation are accurate and easy to explain
• Build a short internal memo on arthritis patient demand, product fit, medical claims, and access barriers
FAQ
What did the survey find?
The survey found that 15.8 percent of arthritis patients had used cannabis in the past year to control pain.
How many patients were included?
The study included 406 arthritis and joint pain patients from three orthopedic clinics in Canada.
How many patients had previously used cannabis for medical purposes?
The study found that 26.3 percent had previously used cannabis for medical purposes.
Did patients think cannabis could reduce pain?
Yes. Patients estimated on average that cannabis could treat 53.6 percent of their pain.
Did patients think cannabis could replace other pain medications?
Patients estimated on average that cannabis could replace 50.4 percent of their analgesic medications.
What is the biggest operator takeaway?
Medical cannabis demand for arthritis and joint pain is real, but operators need responsible education, compliant product claims, clinician engagement, and regulated supply.
SOURCES
International Cannabis Business Conference, Survey Finds 1 In 6 Arthritis Patients Use Cannabis for Joint Pain
https://internationalcbc.com/survey-finds-1-in-6-arthritis-patients-use-cannabis-for-joint-pain/
Journal of International Medical Research, Perceptions regarding the use of cannabis in orthopaedics for treating musculoskeletal joint pain: A survey of arthritis patients
https://journals.sagepub.com/doi/10.1177/03000605261438343
CDC, Arthritis
https://www.cdc.gov/arthritis/index.html
A new survey found that 15.8 percent of arthritis patients had used cannabis in the past year to control pain, while 26.3 percent had previously used cannabis for medical purposes. The bigger lesson is that patient demand continues to grow, but medical cannabis access still needs responsible education, physician guidance, product quality, and compliant claims.